Baxter Announces FDA Approval Of ARTISS Slow Setting Fibrin Sealant In Treatment Of Burn Patients

Baxter Healthcare Corporation announced the U.S. Food and Drug Administration (FDA) approval of ARTISS (Fibrin Sealant (Human)), the first and only slow-setting fibrin sealant indicated for use in adhering skin grafts in adult and pediatric burn patients.